Eisai向美国FDA提交Leqembi® Iqlik™皮下注射起始剂量的生物制品许可补充申请,用于治疗早期阿尔茨海默病并获快速通道资格

美股速递
Sep 03

Eisai公司已启动向美国食品药品监督管理局(FDA)提交Leqembi® Iqlik™ (Lecanemab-Irmb)的滚动式生物制品许可补充申请,该申请涉及皮下注射起始剂量用于治疗早期阿尔茨海默病,并已获得快速通道资格。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10